New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
09:53 EDTVRX, AGNGlass Lewis recommends Allergan investors support calls for special meeting
Pershing Square Capital Management, the largest shareholder of Allergan (AGN), announced that on August 4, Glass Lewis & Co. recommended that Allergan shareholders support Pershing Square’s efforts to call a special meeting of shareholders and that shareholders take the steps necessary under Allergan’s bylaws to call a special meeting. Glass Lewis’s recommendations are relied upon by hundreds of major institutional investment firms, mutual and pension funds and other fiduciaries. At the Special Meeting, Allergan shareholders will have the opportunity to voice their support for a number of critical matters, including the removal of six incumbent members of the Allergan board, the appointment of an independent slate of directors, amendments to Allergan’s bylaws to eliminate onerous restrictions on the calling of a special meeting and certain other actions to improve corporate governance of Allergan. Pershing Square CEO Bill Ackman commented: “We’ve said all along that the Allergan board was more concerned with protecting itself than providing value to its shareholders. We’re pleased Glass Lewis agrees with us on that point and has endorsed the call for a special meeting of Allergan shareholders. We ask Allergan’s board to consider the criticisms reflected in the Glass Lewis report and address them by, among other things, quickly engaging with Valeant (VRX) on its strategically compelling offer to acquire Allergan.”
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use